Welcome to our dedicated page for Baxter International news (Ticker: BAX), a resource for investors and traders seeking the latest updates and insights on Baxter International stock.
Baxter International Inc. (NYSE: BAX) is a global healthcare company dedicated to providing essential renal and hospital products. With a comprehensive portfolio that includes home, acute, and in-center dialysis, sterile IV solutions, infusion systems and devices, parenteral nutrition, biosurgery products, anesthetics, and pharmacy automation, Baxter plays a critical role in expanding access to healthcare worldwide.
Baxter's recent acquisition of Hillrom in late 2021 has significantly enhanced its hospital-focused offerings. This acquisition brought basic equipment like hospital beds under Baxter’s umbrella, along with advanced digital solutions such as smart beds and the Voalte medical communications app. These additions complement Baxter’s legacy operations, which focus on products for patients with acute and chronic kidney failure. Notably, Baxter plans to spin off its renal care segment by mid-2024.
Additionally, Baxter provides a variety of injectable therapies, including IV pumps, administrative sets, and nutritional products, as well as surgical sealants and hemostatic agents used in various care settings. The company’s extensive global footprint and the essential nature of its products and services underscore its commitment to advancing healthcare innovations and improving patient care in both emerging and developed markets.
Baxter’s financial condition remains robust, bolstered by its continuous innovation and strategic partnerships. The company’s employees worldwide are dedicated to building upon a rich heritage of medical breakthroughs, ensuring that Baxter continues to be at the forefront of healthcare advancements.
Baxter International Inc. (NYSE:BAX) will hold a conference call on February 9, 2023, at 7:30 a.m. Central Time to discuss its fourth-quarter 2022 financial results. Interested participants can pre-register through the provided link or access the call via Baxter’s website. The call will also be recorded for future reference. Baxter continues to be a leader in healthcare with a diverse portfolio including critical care, kidney care, and surgical products utilized globally. For more insights, visit www.baxter.com.
Baxter International Inc. (NYSE:BAX) has announced plans to spin off its Renal Care and Acute Therapies units into a publicly traded company within 12-18 months. This restructuring aims to simplify operations, enhance strategic focus, and improve long-term performance. Additionally, Baxter will explore strategic alternatives for its BioPharma Solutions business to optimize its capital structure. The proposed changes are designed to strengthen Baxter's market position and foster innovation, with sales for the renal unit in 2021 reaching $5 billion.
The ExactaMix Pro Automated Compounder from Baxter International (NYSE:BAX), set for release in early 2023, enhances security and user experience while offering superior data reporting capabilities. It will be showcased at the ASHP Midyear Clinical Meeting from Dec. 4-8, 2022. This advanced system is certified to the FDA-recognized UL 2900-2-1 cybersecurity standard and provides features designed for increased efficiency and ease of use, including touchscreen responsiveness and 15 months of data storage. ExactaMix Pro signals a significant advancement in compounding technology.
Baxter International Inc. (NYSE:BAX) will participate in the 5th Annual Evercore ISI HealthCONx Conference on December 1, 2022, at 1:00 p.m. Eastern Time. Chief Financial Officer Jay Saccaro will present at the event. A live webcast will be available on www.baxter.com and can be replayed until May 30, 2023. With a legacy of 90 years, Baxter continues to innovate in areas like diagnostic and critical care solutions across over 100 countries, helping millions of patients and caregivers globally.
Baxter International Inc. (NYSE:BAX) has declared a quarterly cash dividend of $0.29 per share, payable on January 3, 2023. Shareholders of record by December 2, 2022 will receive this dividend. The annual dividend rate is set at $1.16 per share. Baxter continues to maintain its commitment to returning value to shareholders while focusing on innovations in healthcare.
Baxter International Inc. (NYSE:BAX) presented significant data at Kidney Week 2022 demonstrating the benefits of its remote patient management platform, Sharesource, and the Theranova dialyzer. A controlled study revealed that Sharesource improves outcomes for home peritoneal dialysis patients by reducing adverse events. Additionally, ex vivo studies indicated that Theranova effectively removes larger middle-molecule toxins while maintaining albumin stability during hemodialysis. These innovations aim to enhance patient care in response to the global kidney disease crisis.
Baxter International reported third-quarter 2022 revenue of $3.8 billion, a 17% increase on a reported basis. U.S. GAAP EPS was ($5.83), reflecting $3.1 billion in impairment charges from the Hillrom acquisition, attributed to rising interest rates and equity declines. Adjusted EPS was $0.82, a 20% decrease year-over-year. International sales grew 1%, while U.S. sales surged 40%. Despite challenges from supply constraints and competition, Baxter's product innovations continue to drive growth. The company anticipates 17%-18% sales growth for the full year.
Baxter International Inc. (NYSE:BAX) will host a conference call on October 27, 2022, at 7:30 a.m. Central Time to discuss its third-quarter financial results. Interested participants can pre-register for the call via the provided link. The call will also be webcasted through Baxter’s official website, where it will be accessible after the live session. Baxter provides critical healthcare products across multiple sectors, serving patients globally. For more information, visit www.baxter.com.
Baxter International Inc. (NYSE:BAX) has announced a commitment of
FAQ
What is the current stock price of Baxter International (BAX)?
What is the market cap of Baxter International (BAX)?
What does Baxter International Inc. specialize in?
What was the impact of Baxter's acquisition of Hillrom?
What products does Baxter offer for kidney failure patients?
What are some of Baxter's injectable therapies?
What surgical products does Baxter provide?
What is Baxter's plan for its renal care segment?
How does Baxter contribute to global healthcare access?
How does Baxter ensure continuous innovation?
What are some of the digital solutions offered by Baxter?
What is Baxter's commitment to patient care?
